Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) General Information
Description
Portfolio of small molecule acetyl co-A synthetase-2 inhibitor intended for treatment of cancers. The asset includes novel, potent and selective next generation ACSS2i as well as other ACSS2i compounds, including the clinical candidate known as MTB9655.
Contact Information
Corporate Office
- Yavne
- Israel
Corporate Office
- Yavne
- Israel
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) FAQs
-
Where is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) headquartered?
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is headquartered in Yavne, Israel.
-
What industry is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) in?
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s primary industry is Buildings and Property.
-
Is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) a private or public company?
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is a Private company.
-
What is Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s current revenue?
The current revenue for Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) is .
-
Who are Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)’s investors?
Metabomed has invested in Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor).
-
When was Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) acquired?
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) was acquired on 23-Jan-2024.
-
Who acquired Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor)?
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor) was acquired by EpiVario.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process